Last Updated: 11 Jul 2025
Source: Statifacts
The US neurology market size was calculated at USD 1,619 million in 2024 and is predicted to attain around USD 4,909 million by 2034, expanding at a CAGR of 11.73% from 2025 to 2034. The neurological devices and treatments market is growing for reasons such as the greater prevalence of neurological ailments and the aging of the population.
| Industry Worth | Details |
| Market Size in 2025 | USD 1,818 Million |
| Market Size by 2034 | USD 4,909 Million |
| Market Growth Rate from 2025 to 2034 | CAGR of 11.73% |
The neurology market is an inside-out sector of healthcare concerned with diagnosing, treating, and managing patients with diseases of the central and peripheral nervous system. It encompasses variegated neurological disorders, from neurodegenerative diseases such as Alzheimer's to neurovascular disorders such as stroke. The market encompasses diagnostic imaging technologies, biomarkers, surgical equipment, pharmaceuticals, neurostimulators, and digital health platforms. To improve patient outcomes, a multidisciplinary network of neurologists, neurosurgeons, researchers, and other healthcare professionals comes together. On the innovation track stand neuroimaging, artificial intelligence, brain-computer interfaces, and targeted drug therapies. Neuroimaging advancements, augmented BCIs, and AI-based diagnostics are taking the early detection and higher personalized patient care to their furthest level. High demand is also seen in specialized treatments, targeted therapy, and especially deep brain stimulation. Government support, healthcare infrastructure changes, and mental health awareness are all helping create an investment environment for innovation in neurological healthcare.
Increase in prevalence of neurological diseases, aging population, and the rise in awareness of mental health contribute to market growth. Other factors that bring the market to new heights include government initiatives for healthcare and the burgeoning boom of healthcare infrastructure, opening wider avenues for access to healthcare and investment for neurological research.
Artificial intelligence is the revolution of neurology, enhancing diagnosis, personalizing intervention, and developing research. AI algorithms can induce early signs of neurological degenerations, such as a stroke or Alzheimer's, from imaging data and thus, prevent poorer clinical outcomes. There is an opportunity for personalized intervention by evaluating patient-specific data, therapies, and disease progress. AI instruments accelerate discoveries by identifying patterns from large datasets and in drug development. It also holds future possibilities of brain-computer interfacing in precision medicine, but the ethical grounds remain to be seen.
The major market drivers in the U.S. neurology market are an aging population, rising healthcare expenditure, increased prevalence of chronic diseases, and technological advancements.
Rising healthcare expenditure
The US healthcare industry is terrifically growing owing to increased expenditure on health. The healthcare sector is one of the significant GDP allocates by the country, whose healthcare sector comprises investment from the Government and other giant private entities. This kind of financing ensures that advanced medical technologies are now interfaced in numerous settings for medical use. Medical devices are sometimes reimbursed by government insurance plans such as Medicare, Medicaid, and private insurance plans that enhance patient access and affordability. Such spending enables providers to upgrade existing medical equipment, invest in precision diagnostics and minimally invasive surgical technologies; however, it also finances R&D that ignites innovative activities concerning AI-integrated devices, robotics, and telehealth tools. The requirements of value-based care and improved patient outcomes, in turn, promote the demand for efficient and cost-effective medical technologies.
Remote Patient Monitoring
RPM and digital therapeutics are poised to change the shape and character of the U.S. medical device market. RPM devices monitor conditions like diabetes, hypertension, and heart disease on a continuous basis, thus reducing healthcare costs and providing convenience. Digital therapeutics, in contrast, use software to deploy evidence-based behavioral health programs for conditions such as chronic pain and lifestyle disorders via mobile apps. Keeping population health in mind, these systems enable early interventions as well as bolster medication adherence, aid in preventing hospital readmissions, etc. Decentralized-in-patient-and-provider-care models entail an opportunity for medical device manufacturers to go forth and create user-friendly tools connected to the uninterrupted delivery of care at all times day.
The growth of the U.S. neurology market is restrained by factors such as high initial cost, stringent regulations, and cybersecurity.
High treatment cost
High treatment expenses in the U.S. neurology market primarily act as barriers impacting patient access and healthcare outcomes. Neurological diseases such as Alzheimer's, Parkinson's, or even multiple sclerosis, and epilepsy necessitate complicated treatments for life, including high-priced medicines, surgical procedures, constant observation, rehabilitation, and much more specialized care. With the limitation of insurance for newer treatments on approved newer therapies, the matter worsens. Due to the financial burden, consequences include delayed treatment, non-adherence to the prescribed therapies, and further worsening of patient outcomes. Hence, tackling cost barriers helps maintain equal access to neurological care, including extending insurance coverage, improving reimbursement mechanisms, and empowering value-based pricing.
Lack of skilled professionals
Confronting the challenges of specialist neurological care in the United States results in differences in the diagnosis, treatment, and knowledge of neurological conditions. These include the geographic disparities, shortage of neurologists and care centers in rural and underserved areas, and an overall national shortage of neurologists, which leads to long waiting times and pressure on those providing care. An aging population, with ever-more chronic neurological conditions, also helps stimulate increased needs for neurological services, which, however, have not been accommodated in terms of supply. Interference from the healthcare infrastructure further complicates matters, barring technology advancement, few of which may include neuroimaging systems and remote-monitoring tools. The lack of appropriate facilities can be addressed once the gaps in tele-neurology, workforce training, and infrastructure are properly addressed.
The opportunities in the U.S. neurology market are associated with technological advancements, integration of artificial intelligence, and elevated research and development.
Technological advancements
Neurology and neuropharmacology are changing the face of clinical intervention by tailoring therapies according to individual patient profiles, which are essentially constructed from genetic makeup, molecular biomarkers, and brain imaging data. In contrast to common disorders, this treatment is truly suited for long-standing and intricate neurological disorders such as epilepsy, depression, multiple sclerosis, and Parkinsonism. The genetic variations of the patients have been identified, allowing prediction of responses of the patient to a specific kind of medication with some side effects and another without side effects, hence improving the effectiveness of the treatment. Brain imaging has advanced, and now we have fMRIs and PET scans to help with insight into brain structure and function; hence, interventions can be more focused. This approach to intervention ultimately improves patient outcomes and reduces costs associated with healthcare, as ineffective treatments are avoided and readmissions to the hospital are minimized.
Integration of Artificial Intelligence
Neurological revolution brings correction in uncertainty and better treatment planning and thus to the outcome of the patient. Here, Artificial Intelligence does quick and accurate diagnosis of epilepsy and brain tumors using EEGs, MRI scans, and clinical records. Further brain mapping and surgical planning computer tools help the neurosurgeons in navigation for complex surgery. On the contrary, advances in neuroimaging, such as fMRI, PET, and DTI, help to increase knowledge of brain function and connectivity, thus allowing early diagnosis of neurodegenerative disorders. Others include wearable technology and remote patient monitoring systems that track neurological symptoms in real-time: Both are intended to improve disease management and increase patient engagement.
“Our icobrain imaging AI measures are rapidly becoming the standard of care for diagnosis and monitoring of neurological conditions. MRI quantification is crucial to unlock precision medicine, especially in the Alzheimer’s disease care pathway, which is why our partnership with Philips is so well-timed. We have developed the leading AI solutions for brain MRI monitoring, received CPT III code reimbursement in the US, and we will be able to support radiologists, neurologists, and people with neurological conditions at scale through this collaboration.”
“We are excited to enable a collaborative research program that uses the framework of ecological neuroscience to understand brain function.”
The neurostimulation devices segment dominated the U.S. neurology market in 2024. The effectiveness in managing chronic and treatment-resistant neurological conditions is what made neurostimulation devices dominate the U.S. neurology market in 2024. INPs for Parkinson's disease must be one such device with DBS; for chronic pain, there is SCS; and for epilepsy, VNS. These devices send electrical impulses to the selected nerves or brain areas, stimulating or modulating nerve activity and offering relief from symptoms. As awareness grows and technology progresses through time, neurostimulation has embraced both patients and health professionals for treating a wide array of diseases. In spite of surgical implantation being required, maintenance costs, and so forth, clinical benefits and improved quality of life still promote the position of neurostimulation in the neurology market.
The other segment is expected to grow at a notable rate during the forecast period. Non-invasive patient-monitoring, diagnostics, and rehabilitation solutions will be available for patient monitoring. Wearable sensors provide a real-time data stream of physiological data as a basis for early diagnosis and treatment of neurological disorders, set up according to custom needs. BCIs provide communication and control means to persons with paralysis or motor impairments. Robotic rehabilitation devices help conduct neurorehabilitation to restore motor functions in patients suffering from stroke or injury. These instruments promote the outpatient and homecare applications of neurorehabilitation and further facilitate improved access to the care facilities as well as patient participation.
The market is moderately fragmented with local players like Abbott Laboratories, Medtronic, Boston Scientific, Stryker, etc., wishing to take the time to edge their presence through investments, partnerships, acquisitions, and mergers. They also invest in product development and competitive pricing. These strategies will promote market growth and lucrative opportunities for market players
Abbott Laboratories' annual revenue for 2024 was $41.95 billion, which was a 4.59% increase compared to 2023.
Medtronic's Neuroscience portfolio saw a 4.4% increase as reported and a 5.2% organic increase.
Boston Scientific's annual revenue for 2024 was $16.747 billion, a 17.6% increase compared to $14.24 billion in 2023.
Published by Kesiya Chacko
